Skip to main content

Japanese Pharma Astellas Licenses MorphoSys' HuCAL Library

NEW YORK (GenomeWeb News) — Astellas Pharma will use MorphoSys’ HuCAL Gold antibody library in its drug-discovery efforts, MorphoSys said today.
 
Under the agreement, MorphoSys will receive an up-front payment and user fees over the course of the license, which may last up to five years.
 
MorphoSys said it could also receive research funding from preclinical and clinical development of compounds, as well as licensing, milestone, and royalty payments. 
 
Astellas will use the HuCAL library at its facilities in Tsukuba, Japan, and has the option to start antibody projects over the span of the agreement, MorphoSys said.
 
The companies added a collaborative option into the agreement, under which MorphoSys would “generate novel HuCAL antibodies against targets provided by Astellas,” MorphoSys said.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.